 |
 |
 |
|||||||||||
Disease Condition
|
1. Emery CJ, Teng GQ, Liu X et al. Vasoreactions to acute hypoxia, whole lungs and isolated vessels compared: modulation by NO. Respir Physiolo Neurobiol. 2003;134:115-129. 2. Heinonen E, Merilainen P, Hogman M. Administration of nitric oxide into open lung regions: delivery and monitoring. Br J Anaesth. 2003;90:338-342. 3. Aranda M, Pearl RG. Inhaled nitric oxide and pulmonary vasoreactivity. J Clin Monit Comput. 2000;16:393-401. 4. Fesler P, Pagnamenta A, Vachiery JL et al. Single arterial occlusion to locate resistance in patients with pulmonary hypertension. Eur Respir J. 2003;21:31-36. 5. Kao SJ, Peng TC, Lee RP et al. Nitric oxide mediates lung injury induced by ischemia-reperfusion in rats. J Biomed Sci. 2003;10:58-64. 6. Kaftan HA, Clark PL, Norberg M et al. Endogenous production of nitric oxide in endotoxemic piglets. Biol Neonate. 2003;83:42-48. 7. Lee ML, Chiu IS. Inhaled nitric oxide for persistent pulmonary hypertension in a neonate with pulmonary atresia and intact ventricular septum after radiofrequency valvulotomy, balloon valvuloplasty and Blalock-Taussig shunt. Int J Cardiol. 2003;87:273-277. 8. Galie N, Manes A, Branzi A. Emerging medical therapies for pulmonary arterial hypertension. Prog Cardiovasc Dis. 2002;45:213-224. 9. Hurford WE. Inhaled nitric oxide. Respir Care Clin N Am. 2002;8:261-279. 10. Gillies HC, Roblin D, Jackson G. Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. Int J Cardiol. 2002;86:131-141. 11. Keefer LK. Progress toward clinical application of the nitric oxide-releasing diazeniumdiolates. Annu Rev Pharmacol Toxicol. 2003;43:585-607. 12. Sitbon O, Humbert M, Simonneau G. Primary pulmonary hypertension: Current therapy. Prog Cardiovasc Dis. 2002;45:115-128. 13. Jeh HS, Georg SC. Dynamic modeling and simulation of nitric oxide gas delivery to pulmonary arterioles. Ann Biomed Eng. 2002;30:946-960. 14. Chen HI, Hu CT, Wu CY et al. Nitric Oxide in Systemic and Pulmonary Hypertension. J Biomed Sci. 1997;4:244-248. 15. Dweik RA. Pulmonary hypertension and the search for the selective pulmonary vasodilator. Lancet. 2002;360:886-887. 16. Lepore JJ, Maroo A, Pereira NL et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol. 2002;90:677-680. 17. Lowson SM. Inhaled alternatives to nitric oxide. Anesthesiology. 2002;96:1504-1513. 18. Clini E, Ambrosino N. Nitric oxide and pulmonary circulation. Med Sci Monit. 2002;8:RA178-RA182. 19. Huang KL, Wu CP, Kang BH et al. Chronic hypoxia attenuates nitric oxide-dependent hemodynamic responses to acute hypoxia. J Biomed Sci. 2002;9:206-212. 20. Wilkins MR, Aldashev A, Morrell NW. Nitric oxide, phosphodiesterase inhibition, and adaptation to hypoxic conditions. Lancet. 2002;359:1539-1540. 21. Trummer G, Berchtold-Herz M, Martin J et al. Successful treatment of pulmonary hypertension with inhaled nitric oxide after pulmonary embolectomy. Ann Thorac Surg. 2002;73:1299-1301. 22. Hoeper MM, Galie N, Simonneau G et al. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002;165:1209-1216. 23. Hida W, Tun Y, Kikuchi Y et al. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: recent advances in pathophysiology and management. Respirology. 2002;7:3-13. 24. Kemming G, Habler O, Kleen M et al. Searching the ideal inhaled vasodilator: from nitric oxide to prostacyclin. Eur Surg Res. 2002;34:196-202. 25. Deuchar GA, Docherty A, MacLean MR et al. Pulmonary hypertension secondary to left ventricular dysfunction: the role of nitric oxide and endothelin-1 in the control of pulmonary vascular tone. Br J Pharmacol. 2002;135:1060-1068. 26. Maxey TS, Smith CD, Kern JA et al. Beneficial effects of inhaled nitric oxide in adult cardiac surgical patients. Ann Thorac Surg. 2002;73:529-532. 27. Qi J, Du J, Wang L et al. Alleviation of hypoxic pulmonary vascular structural remodeling by L-arginine. Chin Med J (Engl ). 2001;114:933-936. 28. Hayward CS, Macdonald PS, Keogh AM. Inhaled nitric oxide in cardiology. Expert Opin Investig Drugs. 2001;10:1947-1956. 29. Naeije R, Barbera JA. Pulmonary hypertension associated with COPD. Crit Care. 2001;5:286-289. 30. Rashid A, Lehrman S, Romano P et al. Primary pulmonary hypertension. Heart Dis. 2000;2:422-430. 31. Gladwin MT, Schechter AN. Nitric oxide therapy in sickle cell disease. Semin Hematol. 2001;38:333-342. 32. Gorenflo M, Zheng C, Poge A et al. Metabolites of the L-arginine-NO pathway in patients with left-to-right shunt. Clin Lab. 2001;47:441-447. 33. Robbins IM, Barst RJ, Channick RN et al. Pulmonary vasoreactivity in PPH. J Am Coll Cardiol. 2001;38:1267-1268. 34. Braschi A, Iannuzzi M, Belliato M et al. Therapeutic use of nitric oxide in critical settings. Monaldi Arch Chest Dis. 2001;56:177-179. 35. Monnery L, Nanson J, Charlton G. Primary pulmonary hypertension in pregnancy; a role for novel vasodilators. Br J Anaesth. 2001;87:295-298. 36. Cooke JP. A novel mechanism for pulmonary arterial hypertension? Circulation. 2003;108:1420-1421. 37. Cooke JP, Sydow K, Chen J et al. A peculiar result and a fanciful hypothesis regarding L-arginine *. Arterioscler Thromb Vasc Biol. 2003;23:1128. 38. Kandler MA, Von Der HK, Mahfoud S et al. Pilot intervention: aerosolized adrenomedullin reduces pulmonary hypertension. J Pharmacol Exp Ther. 2003;306:1021-1026. 39. Michelakis ED. The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. Heart Fail Rev. 2003;8:5-21. 40. Millatt LJ, Whitley GS, Li D et al. Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation. 2003;108:1493-1498. 41. Morris CR, Morris SM, Jr., Hagar W et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med. 2003;168:63-69. 42. Nagaoka T, Morio Y, Casanova N et al. Rho/Rho-kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol. 2003. 43. Peacock AJ. Treatment of pulmonary hypertension. BMJ. 2003;326:835-836. 44. Sander M, Welling KL, Ravn JB et al. Endogenous NO does not regulate baseline pulmonary pressure, but reduces acute pulmonary hypertension in dogs. Acta Physiol Scand. 2003;178:269-277. 45. Stuhlinger MC, Oka RK, Graf EE et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation. 2003;108:933-938. 46. Asagami T, Abbasi F, Stuelinger M et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism. 2002;51:843-846. 47. Hoeper MM, Galie N, Simonneau G et al. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002;165:1209-1216. 48. Lin KY, Ito A, Asagami T et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. 2002;106:987-992. 49. Qi J, Du J, Wang L et al. Alleviation of hypoxic pulmonary vascular structural remodeling by L-arginine. Chin Med J (Engl ). 2001;114:933-936. 50. Saidy K, al Alaiyan S. The use of L-arginine [correction of F-arginine] and phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide. Indian J Pediatr. 2001;68:175-177. 51. Stuhlinger MC, Tsao PS, Her JH et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 2001;104:2569-2575. 52. Vassalli F, Pierre S, Julien V et al. Inhibition of hypoxic pulmonary vasoconstriction by carbon monoxide in dogs. Crit Care Med. 2001;29:359-366. 53. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 2000;20:2032-2037. 54. Rashid A, Lehrman S, Romano P et al. Primary pulmonary hypertension. Heart Dis. 2000;2:422-430. 55. Roberts JD, Jr., Zapol WM. Inhaled nitric oxide. Semin Perinatol. 2000;24:55-58. 56. Cooke JP. The 1998 Nobel prize in Medicine: clinical implications for 1999 and beyond. Vasc Med. 1999;4:57-60. 57. Hutchison SJ, Sudhir K, Sievers RE et al. Effects of L-arginine on atherogenesis and endothelial dysfunction due to secondhand smoke. Hypertension. 1999;34:44-50. 58. Kavvadia V, Greenough A, Lilley J et al. Plasma arginine levels and the response to inhaled nitric oxide in neonates. Biol Neonate. 1999;76:340-347. 59. Maxwell AJ, Cooke JP. The role of nitric oxide in atherosclerosis. Coron Artery Dis. 1999;10:277-286. 60. Sperling RT, Creager MA. Nitric oxide and pulmonary hypertension. Coron Artery Dis. 1999;10:287-294. 61. Tangphao O, Chalon S, Coulston AM et al. L-arginine and nitric oxide-related compounds in plasma: comparison of normal and arginine-free diets in a 24-h crossover study. Vasc Med. 1999;4:27-32. 62. Kannan MS, Guiang S, Johnson DE. Nitric oxide: biological role and clinical uses. Indian J Pediatr. 1998;65:333-345. 63. Maxwell AJ, Cooke JP. Cardiovascular effects of L-arginine. Curr Opin Nephrol Hypertens. 1998;7:63-70. 64. Moscato G, Malo JL, Bernstein D. Diagnosing occupational asthma: how, how much, how far? Eur Respir J. 2003;21:879-885. 65. Covar RA, Szefler SJ, Martin RJ et al. Relations between exhaled nitric oxide and measures of disease activity among children with mild-to-moderate asthma. J Pediatr. 2003;142:469-475. 66. Lierl MB. Exhaled nitric oxide: a useful aide in pediatric asthma management? J Pediatr. 2003;142:461-462. 67. Payne DN. Nitric oxide in allergic airway inflammation. Curr Opin Allergy Clin Immunol. 2003;3:133-137. 68. Silvestri M, Sabatini F, Sale R et al. Correlations between exhaled nitric oxide levels, blood eosinophilia, and airway obstruction reversibility in childhood asthma are detectable only in atopic individuals. Pediatr Pulmonol. 2003;35:358-363. 69. Prieto L, Gutierrez V, Uixera S et al. Concentrations of exhaled nitric oxide in asthmatics and subjects with allergic rhinitis sensitized to the same pollen allergen. Clin Exp Allergy. 2002;32:1728-1733. 70. Dupont LJ, Demedts MG, Verleden GM. Prospective evaluation of the validity of exhaled nitric oxide for the diagnosis of asthma. Chest. 2003;123:751-756. 71. Sofia M, Maniscalco M, D'Onofrio G et al. Exhaled nitric oxide as a marker of adverse respiratory health effect in environmental disease. Monaldi Arch Chest Dis. 2002;57:182-187. 72. Birrell MA, McCluskie K, Haddad e et al. Pharmacological assessment of the nitric-oxide synthase isoform involved in eosinophilic inflammation in a rat model of sephadex-induced airway inflammation. J Pharmacol Exp Ther. 2003;304:1285-1291. 73. Bates CA, Silkoff PE. Exhaled nitric oxide in asthma: from bench to bedside. J Allergy Clin Immunol. 2003;111:256-262. 74. Silkoff P. Exhaled nitric oxide as a diagnostic tool. Am J Respir Crit Care Med. 2003;167:665-666. 75. Jang AS, Choi IS, Lee JU. Neuronal nitric oxide synthase is associated with airway obstruction in BALB/c mice exposed to ozone. Respiration. 2003;70:95-99. 76. La Grutta S, Gagliardo R, Mirabella F et al. Clinical and biological heterogeneity in children with moderate asthma. Am J Respir Crit Care Med. 2003;167:1490-1495. 77. Paredi P, Kharitonov SA, Barnes PJ. Exhaled breath temperature in asthma. Eur Respir J. 2003;21:195. 78. Kharitonov SA, Barnes PJ. Nitric oxide, nitrotyrosine, and nitric oxide modulators in asthma and chronic obstructive pulmonary disease. Curr Allergy Asthma Rep. 2003;3:121-129. 79. Ricciardolo FL. Multiple roles of nitric oxide in the airways. Thorax. 2003;58:175-182. 80. van dL, I, van den Bosch JM, Zanen P. Reduction of variability of exhaled nitric oxide in healthy volunteers. Respir Med. 2002;96:1014-1020. 81. Paredi P, Kharitonov SA, Barnes PJ. Analysis of expired air for oxidation products. Am J Respir Crit Care Med. 2002;166:S31-S37. 82. Kanazawa H, Hirata K, Yoshikawa J. Nitrogen oxides reduce albuterol-induced bronchodilation in patients with bronchial asthma. Respiration. 2002;69:490-495. 83. Burgaud JL. Therapeutic strategy for asthma: NO body is perfect. Respiration. 2002;69:480-481. 84. Fabbri LM, Romagnoli M, Corbetta L et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167:418-424. 85. Leme AS, Kasahara DI, Nunes MP et al. Exhaled nitric oxide collected with two different mouthpieces: a study in asthmatic patients. Braz J Med Biol Res. 2002;35:1133-1137. 86. Lehtimaki L, Kankaanranta H, Saarelainen S et al. Increased alveolar nitric oxide concentration in asthmatic patients with nocturnal symptoms. Eur Respir J. 2002;20:841-845. 87. Arruda-Chaves E, De Conti D, Tebaldi T. Nitric oxide sera levels as an inflammatory marker in asthma. J Investig Allergol Clin Immunol. 2002;12:120-123. 88. Nevin BJ, Broadley KJ. Nitric oxide in respiratory diseases. Pharmacol Ther. 2002;95:259-293. 89. Evsyukova HV. Aspirin-sensitive asthma due to diffuse neuroendocrine system pathology. Neuroendocrinol Lett. 2002;23:281-285. 90. Baraldi E, de Jongste JC. Measurement of exhaled nitric oxide in children, 2001. Eur Respir J. 2002;20:223-237. 91. Wishah K, Malur A, Raychaudhuri B et al. Nitric oxide blocks inflammatory cytokine secretion triggered by CD23 in monocytes from allergic, asthmatic patients and healthy controls. Ann Allergy Asthma Immunol. 2002;89:78-82. 92. Haahtela T. Assessing airway inflammation: from guessing to quantitative measurements. Ann Med. 2002;34:74-76. 93. Coleman JW. Nitric oxide: a regulator of mast cell activation and mast cell-mediated inflammation. Clin Exp Immunol. 2002;129:4-10. 94. Fischer A, Folkerts G, Geppetti P et al. Mediators of asthma: nitric oxide. Pulm Pharmacol Ther. 2002;15:73-81. 95. Becker AB. Challenges to treatment goals and outcomes in pediatric asthma. J Allergy Clin Immunol. 2002;109:S533-S538. 96. Jang AS, Choi IS, Jeong TK et al. The effect of cigarette smoking on the levels of nitric oxide metabolites in the sputum of patients with acute asthma. J Asthma. 2002;39:211-216. 97. Kissoon N. Acute asthma: under attack. Curr Opin Pediatr. 2002;14:298-302. 98. Borrish L. Sinusitis and asthma: entering the realm of evidence-based medicine. J Allergy Clin Immunol. 2002;109:606-608. 99. Sade K, Kivity S. Nitric oxide in asthma. Isr Med Assoc J. 2002;4:196-199. 100. Kontogiorgis CA, Hadjipavlou-Litina DJ. Non steroidal anti-inflammatory and anti-allergy agents. Curr Med Chem. 2002;9:89-98. 101. Jacoby DB. Virus-induced asthma attacks. JAMA. 2002;287:755-761. 102. Mattes J, Storm Van'S GK, Moeller C et al. Circadian variation of exhaled nitric oxide and urinary eosinophil protein X in asthmatic and healthy children. Pediatr Res. 2002;51:190-194. 103. Lipworth BJ. Duration of steroid therapy determines dose-response effect. Chest. 2002;121:306-307. 104. Khatri SB, Ozkan M, McCarthy K et al. Alterations in exhaled gas profile during allergen-induced asthmatic response. Am J Respir Crit Care Med. 2001;164:1844-1848. 105. Spallarossa D, Battistini E, Silvestri M et al. Time-dependent changes in orally exhaled nitric oxide and pulmonary functions induced by inhaled corticosteroids in childhood asthma. J Asthma. 2001;38:545-553. 106. Stick SM. Exhaled nitric oxide in difficult childhood asthma: more light or still chasing shadows? Am J Respir Crit Care Med. 2001;164:1335-1336. 107. Giroux M, Bremont F, Ferrieres J et al. Exhaled NO in asthmatic children in unpolluted and urban environments. Environ Int. 2001;27:335-340. 108. Andre E, Malheiros A, Cechinel-Filho V et al. Mechanisms underlying the relaxation caused by the sesquiterpene polygodial in vessels from rabbit and guinea-pig. Eur J Pharmacol. 1999;386:47-53. 109. Back M, Walch L, Norel X et al. Modulation of vascular tone and reactivity by nitric oxide in porcine pulmonary arteries and veins. Acta Physiol Scand. 2002;174:9-15. 110. Boer C, Van Der Linden PJ, Scheffer GJ et al. RhoA/Rho kinase and nitric oxide modulate the agonist-induced pulmonary artery diameter response time. Am J Physiol Heart Circ Physiol. 2002;282:H990-H998. 111. Cable DG, Hisamochi K, Schaff HV. A model of xenograft hyperacute rejection attenuates endothelial nitric oxide production: a mechanism for graft vasospasm? J Heart Lung Transplant. 1999;18:177-184. 112. Chai PJ, Williamson JA, Lodge AJ et al. Effects of ischemia on pulmonary dysfunction after cardiopulmonary bypass. Ann Thorac Surg. 1999;67:731-735. 113. Choy WY, Wong YF, Kwan YW et al. Role of mitogen-activated protein kinase pathway in acetylcholine-mediated in vitro relaxation of rat pulmonary artery. Eur J Pharmacol. 2002;434:55-64. 114. Glavind-Kristensen M, Brix-Christensen V, Toennesen E et al. Pulmonary endothelial dysfunction after cardiopulmonary bypass in neonatal pigs. Acta Anaesthesiol Scand. 2002;46:853-859. 115. Higgins RD, Keszler M. Perinatal vascular development. Cardiovasc Res. 2001;51:7-8. 116. Horibe M, Ogawa K, Sohn JT et al. Propofol attenuates acetylcholine-induced pulmonary vasorelaxation: role of nitric oxide and endothelium-derived hyperpolarizing factors. Anesthesiology. 2000;93:447-455. 117. Hucks D, Khan NM, Ward JP. Essential role of L-arginine uptake and protein tyrosine kinase activity for NO-dependent vasorelaxation induced by stretch, isometric tension and cyclic AMP in rat pulmonary arteries. Br J Pharmacol. 2000;131:1475-1481. 118. Johnson LR, Dodam JR, Laughlin MH. Endothelium-dependent relaxation differs in porcine pulmonary arteries from the left and right caudal lobes. J Appl Physiol. 2000;88:827-834. 119. Kim-Park S, Ku DD. Garlic elicits a nitric oxide-dependent relaxation and inhibits hypoxic pulmonary vasoconstriction in rats. Clin Exp Pharmacol Physiol. 2000;27:780-786. 120. Kolber KA, Gao Y, Raj JU. Maturational changes in endothelium-derived nitric oxide-mediated relaxation of ovine pulmonary arteries. Biol Neonate. 2000;77:123-130. 121. Kysela S, Torok J. Contemporary activation of different endothelial receptors accounts for a reserve mechanism of nitric oxide-mediated relaxation. Physiol Res. 2000;49:115-122. 122. Mitani Y, Maruyama J, Maruyama K et al. Exercise training does not alter acetylcholine-induced responses in isolated pulmonary artery from rat. Eur Respir J. 1999;13:622-625. 123. Nyhan D, Gaine S, Hales M et al. Pulmonary vascular endothelial responses are differentially modulated after cardiopulmonary bypass. J Cardiovasc Pharmacol. 1999;34:518-525. 124. Ogawa K, Tanaka S, Murray PA. Inhibitory effects of etomidate and ketamine on endothelium-dependent relaxation in canine pulmonary artery. Anesthesiology. 2001;94:668-677. 125. Priest RM, Hucks D, Ward JP. Potentiation of cyclic AMP-mediated vasorelaxation by phenylephrine in pulmonary arteries of the rat. Br J Pharmacol. 1999;127:291-299. 126. Schneider JC, El Kebir D, Chereau C et al. Involvement of Na(+)/Ca(2+) exchanger in endothelial NO production and endothelium-dependent relaxation. Am J Physiol Heart Circ Physiol. 2002;283:H837-H844. 127. Sun L, Wang DS, Ren W et al. Changes in vasoreactivity of rat pulmonary artery after 7 d tail-suspension. Space Med Med Eng (Beijing). 2001;14:1-5. 128. Thebaud B, Petit T, De Lagausie P et al. Altered guanylyl-cyclase activity in vitro of pulmonary arteries from fetal lambs with congenital diaphragmatic hernia. Am J Respir Cell Mol Biol. 2002;27:42-47. 129. Torok J. Histamine-induced relaxation in pulmonary artery of normotensive and hypertensive rats: relative contribution of prostanoids, nitric oxide and hyperpolarization. Physiol Res. 2000;49:107-114. 130. Tulloh RM, Hislop AA, Haworth SG. Role of NO in recovery from neonatal hypoxic pulmonary hypertension. Thorax. 1999;54:796-804. 131. Villamor E, Perez-Vizcaino F, Cogolludo AL et al. Relaxant effects of carbon monoxide compared with nitric oxide in pulmonary and systemic vessels of newborn piglets. Pediatr Res. 2000;48:546-553. 132. DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets. 2000;1:25-58. 133. Nathan P. Can the cognitive enhancing effects of ginkgo biloba be explained by its pharmacology? Med Hypotheses. 2000;55:491-493. 134. Dinsmore ST. Treatment options for Alzheimer's disease. J Am Osteopath Assoc. 1999;99:S6-S8. 135. Ott BR, Owens NJ. Complementary and alternative medicines for Alzheimer's disease. J Geriatr Psychiatry Neurol. 1998;11:163-173. 136. Kristofikova Z, Klaschka J. In vitro effect of Ginkgo biloba extract (EGb 761) on the activity of presynaptic cholinergic nerve terminals in rat hippocampus. Dement Geriatr Cogn Disord. 1997;8:43-48. 137. Ramassamy C, Clostre F, Christen Y et al. Prevention by a Ginkgo biloba extract (GBE 761) of the dopaminergic neurotoxicity of MPTP. J Pharm Pharmacol. 1990;42:785-789. 138. The role of excitatory amino acids in the actions of abused drugs. NIDA Res Monogr. 1994;140:65-68. 139. Angel-Meza AR, Ramirez-Cortes L, Adame-Gonzalez IG et al. Cerebral GABA release and GAD activity in protein- and tryptophan- restricted rats during development. Int J Dev Neurosci. 2002;20:47-54. 140. Arrigoni E, Rainnie DG, McCarley RW et al. Adenosine-mediated presynaptic modulation of glutamatergic transmission in the laterodorsal tegmentum. J Neurosci. 2001;21:1076-1085. 141. Barbeito L, Cheramy A, Godeheu G et al. Glutamate Receptors of a Quisqualate-Kainate Subtype are Involved in the Presynaptic Regulation of Dopamine Release in the Cat Caudate Nucleus in vivo. Eur J Neurosci. 1990;2:304-311. 142. Belenikin MS, Baskin II, Palyulin VA et al. A new binding mode of competitive antagonists to metabotropic glutamate receptors exemplified by the mGluR1-receptor antagonist AIDA (RS- aminoindan-1,5-dicarboxylic acid). Dokl Biochem Biophys. 2002;384:131-135. 143. Breysse N, Baunez C, Spooren W et al. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci. 2002;22:5669-5678. 144. Car H, Oksztel R, Nadlewska A et al. NMDA receptor antagonists change behavioral activity of rats treated with (S)-4CPG. Pol J Pharmacol. 2001;53:331-339. 145. Chiang AS, Pszczolkowski MA, Liu HP et al. Ionotropic glutamate receptors mediate juvenile hormone synthesis in the cockroach, Diploptera punctata. Insect Biochem Mol Biol. 2002;32:669-678. 146. Dhami GK, Anborgh PH, Dale LB et al. Phosphorylation-independent regulation of metabotropic glutamate receptor signaling by G protein-coupled receptor kinase 2. J Biol Chem. 2002;277:25266-25272. 147. Diaz-Cabiale Z, Vivo M, del Arco A et al. Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci Lett. 2002;324:154-158. 148. Doi A, Ishibashi H, Jinno S et al. Presynaptic inhibition of GABAergic miniature currents by metabotropic glutamate receptor in the rat CNS. 149. Fendt M, Schmid S. Metabotropic glutamate receptors are involved in amygdaloid plasticity. Eur J Neurosci. 2002;15:1535-1541. 150. Giuliano F, Rampin O, Allard J. Neurophysiology and pharmacology of female genital sexual response. J Sex Marital Ther. 2002;28 Suppl 1:101-121. 151. Grosshans DR, Clayton DA, Coultrap SJ et al. Analysis of glutamate receptor surface expression in acute hippocampal slices. Sci STKE. 2002;2002:L8. 152. Holscher C. Metabotropic glutamate receptors control gating of spike transmission in the hippocampus area CA1. Pharmacol Biochem Behav. 2002;73:307-316. 153. Huemmeke M, Eysel UT, Mittmann T. Metabotropic glutamate receptors mediate expression of LTP in slices of rat visual cortex. Eur J Neurosci. 2002;15:1641-1645. 154. Karlsson U, Sjodin J, Angeby MK et al. Glutamate-induced currents reveal three functionally distinct NMDA receptor populations in rat dorsal horn - effects of peripheral nerve lesion and inflammation. Neuroscience. 2002;112:861-868. 155. Katsurabayashi S, Kubota H, Wang ZM et al. cAMP-dependent presynaptic regulation of spontaneous glycinergic IPSCs in mechanically dissociated rat spinal cord neurons. J Neurophysiol. 2001;85:332-340. 156. Lee RK, Jimenez J, Cox AJ et al. Metabotropic glutamate receptors regulate APP processing in hippocampal neurons and cortical astrocytes derived from fetal rats. Ann N Y Acad Sci. 1996;777:338-343. 157. Leinekugel X, Khazipov R, Cannon R et al. Correlated bursts of activity in the neonatal hippocampus in vivo. Science. 2002;296:2049-2052. 158. Li W, Trexler EB, Massey SC. Glutamate receptors at rod bipolar ribbon synapses in the rabbit retina. J Comp Neurol. 2002;448:230-248. 159. Mao L, Wang JQ. Glutamate Cascade to cAMP Response Element-Binding Protein Phosphorylation in Cultured Striatal Neurons through Calcium-Coupled Group I Metabotropic Glutamate Receptors. Mol Pharmacol. 2002;62:473-484. 160. Martin-Ruiz R, Puig MV, Celada P et al. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci. 2001;21:9856-9866. 161. Meeker RB. Metabotropic and NMDA glutamate receptor interactions with osmotic stimuli in supraoptic neurons. Pharmacol Biochem Behav. 2002;73:475-484. 162. Moghaddam B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol Psychiatry. 2002;51:775-787. 163. Neugebauer V. Metabotropic glutamate receptors - important modulators of nociception and pain behavior. Pain. 2002;98:1-8. 164. Pisani A, Bonsi P, Catania MV et al. Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons. J Neurosci. 2002;22:6176-6185. 165. Schoepp DD. Metabotropic glutamate receptors. Pharmacol Biochem Behav. 2002;73:285-286. 166. Sevoz-Couche C, Maisonneuve B, Hamon M et al. Glutamate and NO mediation of the pressor response to 5-HT3 receptor stimulation in the nucleus tractus solitarii. Neuroreport. 2002;13:837-841. 167. Suchak SK, Baloyianni NV, Perkinton MS et al. The 'glial' glutamate transporter, EAAT2 (Glt-1) accounts for high affinity glutamate uptake into adult rodent nerve endings. J Neurochem. 2003;84:522-532. 168. Ulus IH, Wurtman RJ. Metabotropic glutamate receptor agonists increase release of soluble amyloid precursor protein derivatives from rat brain cortical and hippocampal slices. J Pharmacol Exp Ther. 1997;281:149-154. 169. Wang G, Ding S, Yunokuchi K. Glutamate-induced increases in intracellular Ca2+ in cultured rat neocortical neurons. Neuroreport. 2002;13:1051-1056. 170. Chen JF, Moratalla R, Impagnatiello F et al. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci U S A. 2001;98:1970-1975. 171. Chen JF, Xu K, Petzer JP et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci. 2001;21:RC143. 172. Conlay LA, Conant JA, deBros F et al. Caffeine alters plasma adenosine levels. Nature. 1997;389:136. 173. Conlay LA, Evoniuk G, Wurtman RJ. Endogenous adenosine and hemorrhagic shock: effects of caffeine administration or caffeine withdrawal. Proc Natl Acad Sci U S A. 1988;85:4483-4485. 174. Dulloo AG, Seydoux J, Girardier L. Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase inhibition? Metabolism. 1992;41:1233-1241. 175. Dulloo AG, Seydoux J, Girardier L. Peripheral mechanisms of thermogenesis induced by ephedrine and caffeine in brown adipose tissue. Int J Obes. 1991;15:317-326. 176. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci. 2001;24:31-55. 177. Evoniuk G, von Borstel RW, Wurtman RJ. Antagonism of the cardiovascular effects of adenosine by caffeine or 8- (p-sulfophenyl)theophylline. J Pharmacol Exp Ther. 1987;240:428-432. 178. Schwarzschild MA, Chen JF, Ascherio A. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology. 2002;58:1154-1160. 179. Tofovic SP, Zacharia L, Carcillo JA et al. Inhibition of adenosine deaminase attenuates endotoxin-induced release of cytokines in vivo in rats. Shock. 2001;16:196-202. 180. von Borstel RW, Renshaw AA, Wurtman RJ. Adenosine strongly potentiates pressor responses to nicotine in rats. Proc Natl Acad Sci U S A. 1984;81:5599-5603. 181. Barcz E, Sommer E, Janik P et al. Adenosine receptor antagonism causes inhibition of angiogenic activity of human ovarian cancer cells. Oncol Rep. 2000;7:1285-1291. 182. Dulloo AG, Seydoux J, Girardier L. Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase inhibition? Metabolism. 1992;41:1233-1241. 183. Richter A, Hamann M. Effects of adenosine receptor agonists and antagonists in a genetic animal model of primary paroxysmal dystonia. Br J Pharmacol. 2001;134:343-352. 184. Satoh A, Satoh K, Masamune A et al. Activation of adenosine A2a receptor pathway reduces leukocyte infiltration but enhances edema formation in rat caerulein pancreatitis. Pancreas. 2002;24:75-82. 185. Dulloo AG, Seydoux J, Girardier L et al. Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity. Int J Obes Relat Metab Disord. 2000;24:252-258. 186. Luceri C, Caderni G, Sanna A et al. Red wine and black tea polyphenols modulate the expression of cycloxygenase-2, inducible nitric oxide synthase and glutathione- related enzymes in azoxymethane-induced f344 rat colon tumors. J Nutr. 2002;132:1376-1379. 187. Richelle M, Tavazzi I, Offord E. Comparison of the antioxidant activity of commonly consumed polyphenolic beverages (coffee, cocoa, and tea) prepared per cup serving. J Agric Food Chem. 2001;49:3438-3442. 188. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr. 2000;130:2073S-2085S. 189. Aikio O, Vuopala K, Pokela ML et al. Nitrotyrosine and NO synthases in infants with respiratory failure: Influence of inhaled NO. Pediatr Pulmonol. 2003;35:8-16. 190. Heinonen E, Merilainen P, Hogman M. Administration of nitric oxide into open lung regions: delivery and monitoring. Br J Anaesth. 2003;90:338-342. 191. Lee ML, Chiu IS. Inhaled nitric oxide for persistent pulmonary hypertension in a neonate with pulmonary atresia and intact ventricular septum after radiofrequency valvulotomy, balloon valvuloplasty and Blalock-Taussig shunt. Int J Cardiol. 2003;87:273-277. 192. Adatia I. Recent advances in pulmonary vascular disease. Curr Opin Pediatr. 2002;14:292-297. 193. Atz AM, Lefler AK, Fairbrother DL et al. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg. 2002;124:628-629. 194. Castelain V, Chemla D, Humbert M et al. Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. Am J Respir Crit Care Med. 2002;165:338-340. 195. Clini E, Ambrosino N. Nitric oxide and pulmonary circulation. Med Sci Monit. 2002;8:RA178-RA182. 196. Conrad SA, Bidani A. Management of the acute respiratory distress syndrome. Chest Surg Clin N Am. 2002;12:325-354. 197. Dweik RA. Pulmonary hypertension and the search for the selective pulmonary vasodilator. Lancet. 2002;360:886-887. 198. Galie N, Manes A, Branzi A. Emerging medical therapies for pulmonary arterial hypertension. Prog Cardiovasc Dis. 2002;45:213-224. 199. Geary C, Whitsett J. Inhaled nitric oxide for oligohydramnios-induced pulmonary hypoplasia: a report of two cases and review of the literature. J Perinatol. 2002;22:82-85. 200. Ghofrani HA, Wiedemann R, Rose F et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med. 2002;136:515-522. 201. Gianetti J, Bevilacqua S, De Caterina R. Inhaled nitric oxide: more than a selective pulmonary vasodilator. Eur J Clin Invest. 2002;32:628-635. 202. Gillies HC, Roblin D, Jackson G. Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. Int J Cardiol. 2002;86:131-141. 203. Haas KM, Suzuki S, Yamaguchi N et al. Nitric oxide further attenuates pulmonary hypertension in magnesium-treated piglets. Pediatr Int. 2002;44:670-674. 204. Hoeper MM, Galie N, Simonneau G et al. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002;165:1209-1216. 205. Hurford WE. Inhaled nitric oxide. Respir Care Clin N Am. 2002;8:261-279. 206. Kemming G, Habler O, Kleen M et al. Searching the ideal inhaled vasodilator: from nitric oxide to prostacyclin. Eur Surg Res. 2002;34:196-202. 207. Lowson SM. Inhaled alternatives to nitric oxide. Anesthesiology. 2002;96:1504-1513. 208. Mosquera I, Crespo-Leiro MG, Tabuyo T et al. Pulmonary hypertension and right ventricular failure after heart transplantation: usefulness of nitric oxide. Transplant Proc. 2002;34:166-167. 209. Neunteufl T, Berger R, Pacher R. Endothelin receptor antagonists in cardiology clinical trials. Expert Opin Investig Drugs. 2002;11:431-443. 210. Sanchez O, Humbert M, Sitbon O et al. [Pulmonary hypertension associated with connective tissue diseases]. Rev Med Interne. 2002;23:41-54. 211. Sanchez O, Nunes H, Sitbon O et al. [Pulmonary hypertension associated with systemic sclerosis]. Ann Med Interne (Paris). 2002;153:250-259. 212. Sitbon O, Humbert M, Simonneau G. Primary pulmonary hypertension: Current therapy. Prog Cardiovasc Dis. 2002;45:115-128. 213. Su BH, Lin TW, Lin HC et al. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn: four-year experience in a single medical center. Acta Paediatr Taiwan. 2002;43:259-264. 214. Ware LE. Inhaled nitric oxide in infants and children. Crit Care Nurs Clin North Am. 2002;14:1-6. 215. Braschi A, Iannuzzi M, Belliato M et al. Therapeutic use of nitric oxide in critical settings. Monaldi Arch Chest Dis. 2001;56:177-179. 216. Channick RN, Rubin LJ. New and experimental therapies for pulmonary hypertension. Clin Chest Med. 2001;22:539-545. 217. Cracowski JL, Cracowski C, Bessard G et al. Increased lipid peroxidation in patients with pulmonary hypertension. Am J Respir Crit Care Med. 2001;164:1038-1042. 218. Cremona G. Nitric oxide and control of pulmonary vascular resistance. Monaldi Arch Chest Dis. 2001;56:158-164. 219. De Backer TL, Smedema JP, Carlier SG. Current management of primary pulmonary hypertension. BioDrugs. 2001;15:801-817. 220. Gladwin MT, Schechter AN. Nitric oxide therapy in sickle cell disease. Semin Hematol. 2001;38:333-342. 221. Hayward CS, Macdonald PS, Keogh AM. Inhaled nitric oxide in cardiology. Expert Opin Investig Drugs. 2001;10:1947-1956. 222. McMahon CJ, Kadkin J, Nihill MR. Rapid regression of primary pulmonary hypertension. Heart. 2001;86:E1. 223. Naeije R, Barbera JA. Pulmonary hypertension associated with COPD. Crit Care. 2001;5:286-289. 224. Robbins IM, Barst RJ, Channick RN et al. Pulmonary vasoreactivity in PPH. J Am Coll Cardiol. 2001;38:1267-1268. 225. Saidy K, al Alaiyan S. The use of L-arginine [correction of F-arginine] and phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide. Indian J Pediatr. 2001;68:175-177. 226. Zhao L, Mason NA, Morrell NW et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation. 2001;104:424-428. 227. Ashutosh K, Phadke K, Jackson JF et al. Use of nitric oxide inhalation in chronic obstructive pulmonary disease. Thorax. 2000;55:109-113. 228. Bigatello LM. Nitric oxide: modulation of the pulmonary circulation. Minerva Anestesiol. 2000;66:307-313. 229. Ferlito S. Cardiovascular diseases and nitric oxide in humans. Minerva Cardioangiol. 2000;48:379-386. 230. Fike CD, Kaplowitz MR, Rehorst-Paea LA et al. L-Arginine increases nitric oxide production in isolated lungs of chronically hypoxic newborn pigs. J Appl Physiol. 2000;88:1797-1803. 231. Hampl V, Herget J. Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. Physiol Rev. 2000;80:1337-1372. 232. Redding JS, Cooke JE. Management of pulmonary edema. AORN J. 1975;21:659-60, 662, 664. 233. Redding JS, Cooke JE. Management of pulmonary edema. AORN J. 1975;21:659-60, 662, 664. 234. Spallarossa D, Battistini E, Silvestri M et al. Steroid-naive adolescents with mild intermittent allergic asthma have airway hyperresponsiveness and elevated exhaled nitric oxide levels. J Asthma. 2003;40:301-310. 235. Malmberg LP, Pelkonen AS, Haahtela T et al. Exhaled nitric oxide rather than lung function distinguishes preschool children with probable asthma. Thorax. 2003;58:494-499. 236. Moscato G, Malo JL, Bernstein D. Diagnosing occupational asthma: how, how much, how far? Eur Respir J. 2003;21:879-885. 237. Covar RA, Szefler SJ, Martin RJ et al. Relations between exhaled nitric oxide and measures of disease activity among children with mild-to-moderate asthma. J Pediatr. 2003;142:469-475. 238. Payne DN. Nitric oxide in allergic airway inflammation. Curr Opin Allergy Clin Immunol. 2003;3:133-137. 239. Zambrano JC, Carper HT, Rakes GP et al. Experimental rhinovirus challenges in adults with mild asthma: response to infection in relation to IgE. J Allergy Clin Immunol. 2003;111:1008-1016. 240. Hansel TT, Kharitonov SA, Donnelly LE et al. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB J. 2003;17:1298-1300. 241. Katarzyna K, Dariusz Z. [Exhaled nitric oxide in various respiratory diseases]. Pneumonol Alergol Pol. 2002;70:509-517. 242. Lopuhaa CE, Koopmans JG, Jansen HM et al. Similar levels of nitric oxide in exhaled air in non-asthmatic rhinitis and asthma after bronchial allergen challenge. Allergy. 2003;58:300-305. 243. Iuldasheva IA, Aliavi AI, Arinova MI. [Pulmonary hypertension and the specifics of nitric oxide synthesis in patients with bronchial asthma]. Klin Med (Mosk). 2003;81:39-41. 244. Kharitonov SA, Gonio F, Kelly C et al. Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur Respir J. 2003;21:433-438. 245. Prieto L, Gutierrez V, Uixera S et al. Concentrations of exhaled nitric oxide in asthmatics and subjects with allergic rhinitis sensitized to the same pollen allergen. Clin Exp Allergy. 2002;32:1728-1733. 246. Baraldi E, Ghiro L, Piovan V et al. Safety and success of exhaled breath condensate collection in asthma. Arch Dis Child. 2003;88:358-360. 247. Maniscalco M, Vatrella A, Pelaia G et al. Inhaled ultrasonically nebulized distilled water decreases exhaled nitric oxide in asthma. Lung. 2002;180:319-326. 248. Sofia M, Maniscalco M, D'Onofrio G et al. Exhaled nitric oxide as a marker of adverse respiratory health effect in environmental disease. Monaldi Arch Chest Dis. 2002;57:182-187. 249. Birrell MA, McCluskie K, Haddad e et al. Pharmacological assessment of the nitric-oxide synthase isoform involved in eosinophilic inflammation in a rat model of sephadex-induced airway inflammation. J Pharmacol Exp Ther. 2003;304:1285-1291. 250. Bates CA, Silkoff PE. Exhaled nitric oxide in asthma: from bench to bedside. J Allergy Clin Immunol. 2003;111:256-262. 251. Silkoff P. Exhaled nitric oxide as a diagnostic tool. Am J Respir Crit Care Med. 2003;167:665-666. 252. Ricciardolo FL. Multiple roles of nitric oxide in the airways. Thorax. 2003;58:175-182. 253. Eynott PR, Paavolainen N, Groneberg DA et al. Role of nitric oxide in chronic allergen-induced airway cell proliferation and inflammation. J Pharmacol Exp Ther. 2003;304:22-29. 254. Paredi P, Kharitonov SA, Barnes PJ. Analysis of expired air for oxidation products. Am J Respir Crit Care Med. 2002;166:S31-S37. 255. Leme AS, Kasahara DI, Nunes MP et al. Exhaled nitric oxide collected with two different mouthpieces: a study in asthmatic patients. Braz J Med Biol Res. 2002;35:1133-1137. 256. Ekroos H, Karjalainen J, Sarna S et al. Short-term variability of exhaled nitric oxide in young male patients with mild asthma and in healthy subjects. Respir Med. 2002;96:895-900. 257. Pijnenburg MW, Lissenberg ET, Hofhuis W et al. Exhaled nitric oxide measurements with dynamic flow restriction in children aged 4-8 yrs. Eur Respir J. 2002;20:919-924. 258. Zwissler B. [Inhaled vasodilators]. Anaesthesist. 2002;51:603-624. 259. Suman OE, Beck KC. Role of airway endogenous nitric oxide on lung function during and after exercise in mild asthma. J Appl Physiol. 2002;93:1932-1938. 260. Jones SL, Herbison P, Cowan JO et al. Exhaled NO and assessment of anti-inflammatory effects of inhaled steroid: dose-response relationship. Eur Respir J. 2002;20:601-608. 261. Baraldi E, de Jongste JC. Measurement of exhaled nitric oxide in children, 2001. Eur Respir J. 2002;20:223-237. 262. Balboa DP, Rueda ES, Aleo LE et al. [Exhaled nitric oxide in healthy and asthmatic children]. An Esp Pediatr. 2002;57:12-17. 263. Kanazawa H, Asai K, Hirata K et al. Vascular involvement in exercise-induced airway narrowing in patients with bronchial asthma. Chest. 2002;122:166-170. 264. Kharitonov SA, Barnes PJ. Biomarkers of some pulmonary diseases in exhaled breath. Biomarkers. 2002;7:1-32. 265. Coleman JW. Nitric oxide: a regulator of mast cell activation and mast cell-mediated inflammation. Clin Exp Immunol. 2002;129:4-10. 266. Kissoon N. Acute asthma: under attack. Curr Opin Pediatr. 2002;14:298-302. 267. Kharitonov SA, Barnes PJ. Exhaled markers of inflammation. Curr Opin Allergy Clin Immunol. 2001;1:217-224. 268. ten Brinke A, Grootendorst DC, Schmidt JT et al. Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol. 2002;109:621-626. 269. Sade K, Kivity S. Nitric oxide in asthma. Isr Med Assoc J. 2002;4:196-199. 270. L-arginine-derived nitric oxide and the cell-mediated immune response. 39th Forum in Immunology. Res Immunol. 1991;142:551-602. 271. Does supplemental arginine alter immune function following major surgery? Nutr Rev. 1993;51:54-56. 272. Abbasi F, Asagmi T, Cooke JP et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol. 2001;88:1201-1203. 273. Albertini M, Clement MG. In pigs, inhaled nitric oxide (NO) counterbalances PAF-induced pulmonary hypertension. Prostaglandins Leukot Essent Fatty Acids. 1994;51:357-362. 274. Alexander JW. Specific nutrients and the immune response. Nutrition. 1995;11:229-232. 275. Angele MK, Smail N, Ayala A et al. L-arginine: a unique amino acid for restoring the depressed macrophage functions after trauma-hemorrhage. J Trauma. 1999;46:34-41. 276. Angele MK, Fitzal F, Smail N et al. L-arginine attenuates trauma-hemorrhage-induced liver injury. Crit Care Med. 2000;28:3242-3248. 277. Arnal JF, Dinh-Xuan AT, Pueyo M et al. Endothelium-derived nitric oxide and vascular physiology and pathology. Cell Mol Life Sci. 1999;55:1078-1087. 278. Ashutosh K. Nitric oxide and asthma: a review. Curr Opin Pulm Med. 2000;6:21-25. 279. Boer J, Duyvendak M, Schuurman FE et al. Role of L-arginine in the deficiency of nitric oxide and airway hyperreactivity after the allergen-induced early asthmatic reaction in guinea-pigs. Br J Pharmacol. 1999;128:1114-1120. 280. Boer J, Duyvendak M, Schuurman FE et al. Role of L-arginine in the deficiency of nitric oxide and airway hyperreactivity after the allergen-induced early asthmatic reaction in guinea-pigs. Br J Pharmacol. 1999;128:1114-1120. 281. Castillo L, DeRojas-Walker T, Yu YM et al. Whole body arginine metabolism and nitric oxide synthesis in newborns with persistent pulmonary hypertension. Pediatr Res. 1995;38:17-24. 282. Cen Y, Luo XS, Liu XX. [Effect of L-arginine supplementation on partial-thickness burned patients]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 1999;13:227-231. 283. Cerra FB. Nutrient modulation of inflammatory and immune function. Am J Surg. 1991;161:230-234. 284. Cooke JP, Andon NA, Girerd XJ et al. Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta. Circulation. 1991;83:1057-1062. 285. Cooke JP, Dzau J, Creager A. Endothelial dysfunction in hypercholesterolemia is corrected by L-arginine. Basic Res Cardiol. 1991;86 Suppl 2:173-181. 286. Cooke JP, Tsao PS. Arginine: a new therapy for atherosclerosis? Circulation. 1997;95:311-312. 287. Cooke JP. Nutriceuticals for cardiovascular health. Am J Cardiol. 1998;82:43S-46S. 288. Cooke JP. The endothelium: a new target for therapy. Vasc Med. 2000;5:49-53. 289. Cooke JP, Losordo DW. Nitric oxide and angiogenesis. Circulation. 2002;105:2133-2135. 290. Cooke JP. A novel mechanism for pulmonary arterial hypertension? Circulation. 2003;108:1420-1421. 291. Creager MA, Gallagher SJ, Girerd XJ et al. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 1992;90:1248-1253. 292. Cremona G, Wood AM, Hall LW et al. Effect of inhibitors of nitric oxide release and action on vascular tone in isolated lungs of pig, sheep, dog and man. J Physiol. 1994;481 ( Pt 1):185-195. 293. de Gouw HW, Verbruggen MB, Twiss IM et al. Effect of oral L-arginine on airway hyperresponsiveness to histamine in asthma. Thorax. 1999;54:1033-1035. 294. de Gouw HW, Marshall-Partridge SJ, van d, V et al. Role of nitric oxide in the airway response to exercise in healthy and asthmatic subjects. J Appl Physiol. 2001;90:586-592. 295. de lR, I, Roson MI, Vega GW et al. Effect of oral L-arginine administration for three weeks in two kidney-two clip hypertensive rats. Arch Physiol Biochem. 2000;108:415-421. 296. Efron DT, Barbul A. Modulation of inflammation and immunity by arginine supplements. Curr Opin Clin Nutr Metab Care. 1998;1:531-538. 297. Efron DT, Barbul A. Arginine and immunonutrition: a reevaluation. Nutrition. 2000;16:73-74. 298. Evoy D, Lieberman MD, Fahey TJ, III et al. Immunonutrition: the role of arginine. Nutrition. 1998;14:611-617. 299. Fagan JM, Rex SE, Hayes-Licitra SA et al. L-arginine reduces right heart hypertrophy in hypoxia-induced pulmonary hypertension. Biochem Biophys Res Commun. 1999;254:100-103. 300. Field CJ, Johnson I, Pratt VC. Glutamine and arginine: immunonutrients for improved health. Med Sci Sports Exerc. 2000;32:S377-S388. 301. Galie N, Manes A, Branzi A. Emerging medical therapies for pulmonary arterial hypertension. Prog Cardiovasc Dis. 2002;45:213-224. 302. Gonce SJ, Peck MD, Alexander JW et al. Arginine supplementation and its effect on established peritonitis in guinea pigs. JPEN J Parenter Enteral Nutr. 1990;14:237-244. 303. Bonina L, Nash AA, Arena A et al. T cell-macrophage interaction in arginase-mediated resistance to herpes simplex virus. Virus Res. 1984;1:501-505. 304. Denis M. Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M. avium: killing effector mechanism depends on the generation of reactive nitrogen intermediates. J Leukoc Biol. 1991;49:380-387. 305. Espanol A, Eijan AM, Mazzoni E et al. Nitric oxide synthase, arginase and cyclooxygenase are involved in muscarinic receptor activation in different murine mammary adenocarcinoma cell lines. Int J Mol Med. 2002;9:651-657. 306. Gobert AP, McGee DJ, Akhtar M et al. Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: a strategy for bacterial survival. Proc Natl Acad Sci U S A. 2001;98:13844-13849. 307. Hammermann R, Hirschmann J, Hey C et al. Cationic proteins inhibit L-arginine uptake in rat alveolar macrophages and tracheal epithelial cells. Implications for nitric oxide synthesis. Am J Respir Cell Mol Biol. 1999;21:155-162. 308. Hammermann R, Hirschmann J, Hey C et al. Cationic proteins inhibit L-arginine uptake in rat alveolar macrophages and tracheal epithelial cells. Implications for nitric oxide synthesis. Am J Respir Cell Mol Biol. 1999;21:155-162. 309. Huang J, DeGraves FJ, Lenz SD et al. The quantity of nitric oxide released by macrophages regulates Chlamydia-induced disease. Proc Natl Acad Sci U S A. 2002;99:3914-3919. 310. Hutchison SJ, Sievers RE, Zhu BQ et al. Secondhand tobacco smoke impairs rabbit pulmonary artery endothelium-dependent relaxation. Chest. 2001;120:2004-2012. 311. James SL, Glaven JA. Effects of inhibitors of tumoricidal activity upon schistosomulum killing by activated macrophages. Infect Immun. 1987;55:3174-3180. 312. Kung JT, Brooks SB, Jakway JP et al. Suppression of in vitro cytotoxic response by macrophages due to induced arginase. J Exp Med. 1977;146:665-672. 313. Langle F, Roth E, Steininger R et al. Arginase release following liver reperfusion. Evidence of hemodynamic action of arginase infusions. Transplantation. 1995;59:1542-1549. 314. Langle F, Roth E, Steininger R et al. Arginase release following liver reperfusion. Evidence of hemodynamic action of arginase infusions. Transplantation. 1995;59:1542-1549. 315. Martin-Sanz P, Bosca L, Olmedilla L et al. Presence of a nitric oxide synthase inhibitor in the graft efflux during reperfusion in human liver transplantation. Clin Transplant. 1999;13:221-230. 316. Meurs H, McKay S, Maarsingh H et al. Increased arginase activity underlies allergen-induced deficiency of cNOS-derived nitric oxide and airway hyperresponsiveness. Br J Pharmacol. 2002;136:391-398. 317. Meurs H, McKay S, Maarsingh H et al. Increased arginase activity underlies allergen-induced deficiency of cNOS-derived nitric oxide and airway hyperresponsiveness. Br J Pharmacol. 2002;136:391-398. 318. Meurs H, Maarsingh H, Zaagsma J. Arginase and asthma: novel insights into nitric oxide homeostasis and airway hyperresponsiveness. Trends Pharmacol Sci. 2003;24:450-455. 319. Morris CR, Morris SM, Jr., Hagar W et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med. 2003;168:63-69. 320. Olds GR, Ellner JJ, Kearse LA, Jr. et al. Role of arginase in killing of schistosomula of Schistosoma mansoni. J Exp Med. 1980;151:1557-1562. 321. Pereira CA, Soler G, Modolell M. Anti-MHV3 state induced by IFN gamma in macrophages is not related to arginine metabolism. Arch Virol. 1997;142:2001-2010. 322. Sahach VF, Baziliuk OV, Kotsiuruba AV et al. [Disorders of endothelium-dependent vascular reactions and of the arginase and NO-synthase pathways of L-arginine metabolism in arterial hypertension]. Fiziol Zh. 2000;46:3-13. 323. Todd CD, Cooke JE, Mullen RT et al. Regulation of loblolly pine (Pinus taeda L.) arginase in developing seedling tissue during germination and post-germinative growth. Plant Mol Biol. 2001;45:555-565. 324. Vercelli D. Arginase: marker, effector, or candidate gene for asthma? J Clin Invest. 2003;111:1815-1817. 325. Zimmermann N, King NE, Laporte J et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest. 2003;111:1863-1874.
|
||||||||||
 |
|||||||||||
|
|||||||||||
 |
|||||||||||
